September 4, 2013Open Access

Cabozantinib in Progressive Medullary Thyroid Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease. This dose of cabozantinib was associated with significant but manageable toxicity.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Elisei et al. (Wed,) studied this question.

synapsesocial.com/papers/69da2667a6045d71bfa3c3f9 https://doi.org/https://doi.org/10.1200/jco.2012.48.4659

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer2011 · 551 citations
2Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression2011 · 103 citations
3An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.2012 · 92 citations
4The RET Kinase Inhibitor NVP-AST487 Blocks Growth and Calcitonin Gene Expression through Distinct Mechanisms in Medullary Thyroid Cancer Cells2007 · 112 citations
5Vascular Endothelial Growth Factor Expression Is Higher in Differentiated Thyroid Cancer than in Normal or Benign Thyroid<sup>1</sup>1997 · 155 citations

Me gusta

Guardar

Ver artículo completo